Monday - April 14, 2025

LOGIN  |  REGISTER
Assertio

IGC Pharma (NYSEAMEX: IGC) Stock Quote

Last Trade: US$0.28 -0.0005 -0.18
Volume: 232,912
5-Day Change: 3.33%
YTD Change: -16.96%
Market Cap: US$21.610M

Latest News From IGC Pharma

POTOMAC, MARYLAND / ACCESS Newswire / April 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial with the addition of Butler Hospital's Memory and Aging Program, a nationally recognized research center affiliated with the Warren Alpert Medical School of Brown University, in Providence, Rhode Island. The site will support... Read More
POTOMAC, MARYLAND / ACCESS Newswire / April 1, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitation in Alzheimer's dementia, to MIND Institute at Miami Jewish Health in Miami, Florida. This addition further advances the company's efforts to accelerate the trial's completion and builds on promising interim data... Read More
IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer's POTOMAC, MD / ACCESS Newswire / March 26, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced additional positive interim results from its ongoing Phase 2 clinical trial on IGC-AD1, an investigational treatment for agitation in dementia due to Alzheimer's disease. Based on the interim analysis at week 2... Read More
POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the addition of a new clinical site at Hamilton Health Sciences (HHS) in Ontario, Canada. This expansion marks a key milestone in IGC Pharma's strategy to advance IGC-AD1 toward commercialization, accelerating patient enrollment and... Read More
POTOMAC, MARYLAND / ACCESS Newswire / March 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of a new trial site at BayCare's St. Anthony's Hospital in St. Petersburg, Florida as part of its ongoing Phase 2 CALMA trial evaluating IGC-AD1, the Company's lead therapeutic candidate, for the treatment of agitation in Alzheimer's dementia. IGC-AD1 is a combination... Read More
POTOMAC, MARYLAND / ACCESS Newswire / March 12, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Ascendiant Capital Markets has issued a coverage report entitled "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25" All reports on IGC Pharma prepared by analysts represent the views of those analysts and are... Read More
POTOMAC, MARYLAND / ACCESS Newswire / March 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Alliance Global Partners (AGP) has issued an analyst update research report entitled " Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily... Read More
POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development of a new AI-driven model designed to improve the diagnosis of Alzheimer's disease (AD) and other causes of dementia. With Alzheimer's accounting for approximately 60-80% of all dementia cases, alongside other conditions... Read More
New science-backed formulations designed to support cellular health, energy metabolism, and cognitive function POTOMAC, MD / ACCESS Newswire / February 20, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is expanding its Holiby™ wellness brand with the launch of two new product lines-Longevity and Renew-specifically designed to meet the increasing demand for anti-aging and cellular health... Read More
POTOMAC, MARYLAND / ACCESS Newswire / February 18, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results for the third fiscal quarter of 2025 ended December 31, 2024. "The third quarter of fiscal 2025 was marked by our progress in advancing IGC-AD1 in our Phase 2 CALMA trial aimed at reducing agitation in Alzheimer's," said Mr. Ram Mukunda, CEO. "We are also planning to... Read More
Product Launch Leverages IGC's State-Of-The-Art Manufacturing Facility To Support Revenue-Generating Brand for Immunity & Energy POTOMAC, MD / ACCESS Newswire / February 11, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the launch of Holiby™, a wellness brand offering scientifically formulated products for immune defense and sustained energy . This strategic expansion into the... Read More
POTOMAC, MD / ACCESS Newswire / January 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is proud to announce its selection as one of the top 15 finalists in the PREPARE Challenge - Phase 2: Model Arena (Acoustic Track), organized by the National Institute on Aging (NIA). This recognition highlights IGC's innovative application of artificial intelligence (AI) and machine learning to advance... Read More
POTOMAC, MD / ACCESS Newswire / January 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the appointment of Terry McAuliffe, the 72nd Governor of Virginia, as a strategic advisor. Governor McAuliffe's extensive leadership experience across public and private sectors will play a pivotal role in advancing IGC Pharma's mission to redefine Alzheimer's care and position the... Read More
POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Thursday, January 23, 2025, at 1:00 pm ET. During the session, IGC Pharma's management will provide insights into the Company's recent progress, including advancements in its... Read More
POTOMAC, MD / ACCESSWIRE / December 19, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced that the Company's management team will participate in BIO Partnering @ JPM, scheduled alongside the J.P. Morgan 43 rd Annual Healthcare Conference 2025. Management will be available for in-person and virtual meetings. Details of the events are as follows: Event: BIO Partnering @ JPM Date: January 13 -... Read More
New trials to evaluate IGC-AD1's potential impact on amyloid plaque, tau tangles, and cognitive decline in Alzheimer's disease Expanded research positions IGC-AD1 as a potential treatment targeting the underlying disease pathology of Alzheimer's POTOMAC, MARYLAND / ACCESSWIRE / December 2, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today an expansion of its clinical research program... Read More
Interim results indicate cognitive improvement in the active treatment group compared to placebo No serious adverse events or deaths reported in the trial POTOMAC, Md. / Nov 25, 2024 / Business Wire / IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") today announced additional interim data from its ongoing Phase 2 clinical trial evaluating IGC-AD1. The trial focuses on agitation in Alzheimer's as its... Read More
POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results and strategic advancements for the second fiscal quarter of 2025 ended September30, 2024. The quarter was marked by significant progress in the Company's pipeline, particularly in the development of potential treatments for Alzheimer's and other neurological and metabolic... Read More
POTOMAC, MD / ACCESSWIRE / November 6, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the publication of a new interview with CEO Ram Mukunda, now available as part of the IMS Spotlight Series. In the interview, Ram Mukunda discusses IGC's strategic expansion into metabolic and neurological markets, specifically addressing the potential of GLP-1 agonists in both Alzheimer's... Read More
Company Expands Phase 2 trial to Canada POTOMAC, MD / ACCESSWIRE / October 17, 2024 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced enrollment of patients at the Baycrest Academy for Research and Education in Toronto, Ontario, Canada, as part of the Company's ongoing Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer's dementia. Agitation affects between 40-80% of... Read More
POTOMAC, MD / ACCESSWIRE / October 3, 2024 / IGC Pharma, Inc. (NYSE American:IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), with its entry of the Mexican Health and Aging Study ("MHAS") database The PREPARE Challenge is sponsored by the National Institute on Aging ("NIA"), an institute of the National... Read More
IGC-AD1 demonstrates the potential to modify tau and improve spatial memory Data supports the initiation of clinical trials investigating IGC-AD1 as a treatment for Alzheimer's disease POTOMAC, Md. / Sep 18, 2024 / Business Wire / IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") today announced data that reinforces the therapeutic potential of IGC-AD1 as a disease-modifying treatment for Alzheimer's... Read More
POTOMAC, Md. / Sep 04, 2024 / Business Wire / IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") announced today that the Company is advancing its proprietary formulation, IGC-AD1, toward clinical trials as a potential anti-amyloid disease-modifying treatment for Alzheimer's disease. Following the FDA's 2023 approval of two groundbreaking anti-amyloid drugs, Donanemab (Eli Lilly) and Lecanemab (Eisai and... Read More
POTOMAC, Md. / Aug 26, 2024 / Business Wire / IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on August 23, 2023 (the “Annual Meeting”), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 8, 2024, were passed by the requisite vote of the stockholders. Only stockholders of... Read More
IGC-1C Targets Tau Protein and GLP-1 Receptor, Offering a Multi-Pathway Approach to Neurodegenerative and Metabolic Disease Treatment POTOMAC, Md. / Aug 22, 2024 / Business Wire / IGC Pharma, Inc . (NYSE American: IGC) ("IGC Pharma" or the "Company") today announced preclinical research demonstrating the therapeutic potential of IGC-1C, a novel small-molecule modulator. The findings show that IGC-1C targets tau protein phase... Read More
Artificial Intelligence Modelling Reveals New Possibilities for Metabolic and Neurological Therapies POTOMAC, Md. / Aug 20, 2024 / Business Wire / IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") today announced that the Company's proprietary molecule, IGC-1A, has been identified as a potential GLP-1 agonist, as a result of the Company's state-of-the-art Artificial Intelligence ("AI") modeling. This... Read More
POTOMAC, Md. / Aug 08, 2024 / Business Wire / IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the first fiscal quarter of 2025 ended June 30, 2024. Q1 FY2025 Company’s Highlights On April 9, 2024, the Company welcomed Pablo Arbelaez, Ph.D., a renowned AI expert and researcher, to support the development of the Phase 2 clinical trial of IGC-AD1, the lead therapeutic... Read More
POTOMAC, Md. / Jul 18, 2024 / Business Wire / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) announces that Alliance Global Partners (AGP) has issued an analyst coverage research report on the Company’s common stock. All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy,... Read More